CTI BioPharma Corp. (CTIC) financial statements (2020 and earlier)

Company profile

Business Address 3101 WESTERN AVENUE
SEATTLE, WA 98121
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:346727441287172
Cash and cash equivalents313627441287172
Short-term investments331     
Other undisclosed cash, cash equivalents, and short-term investments0(0)     
Restricted cash and investments  16    
Receivables  00020
Inventory, net of allowances, customer advances and progress billings  12345
Inventory  12345
Other undisclosed current assets215310434
Total current assets:368247561358181
Noncurrent Assets
Property, plant and equipment1223455
Other noncurrent assets9665678
Total noncurrent assets:1178891213
TOTAL ASSETS:469055641449294
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities12171632333218
Accounts payable 4371165
Accrued liabilities1213142522209
Employee-related liabilities     63
Taxes payable     0 
Debt55083793
Derivative instruments and hedges, liabilities      1
Deferred revenue and credits10111
Other liabilities2111200
Other undisclosed current liabilities     (6)(3)
Total current liabilities:18231941723620
Noncurrent Liabilities
Long-term debt and lease obligation49141119810
Long-term debt, excluding current maturities49141119810
Liabilities, other than long-term debt55645127
Deferred revenue and credits01162
Other liabilities5554466
Other undisclosed noncurrent liabilities     (4) 
Total noncurrent liabilities:10142015251617
Total liabilities:28373956975238
Temporary equity, carrying amount     113
Stockholders' equity
Stockholders' equity attributable to parent, including:24592213524245
Preferred stock  1    
Common stock00     
Additional paid in capital2,2992,294     
Accumulated other comprehensive loss(12)(11)(6)(7)(7)(6)(8)
Accumulated deficit(2,264)(2,225)(2,195)(2,150)(2,098)(1,976)(1,880)
Other undisclosed stockholders' equity attributable to parent  2,2222,1702,1572,0241,933
Stockholders' equity attributable to noncontrolling interest(6)(6)(6)(6)(5)(3)(2)
Total stockholders' equity:1853168473843
TOTAL LIABILITIES AND EQUITY:469055641449294

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues3262557166035
Revenue, net2557167735
Cost of revenue(1)(5)(0) (2)(1) 
Cost of goods and services sold (1)(0) (2)(1) 
Gross profit:3222557145935
Operating expenses(43)(55)(64)(110)(131)(147)(95)
Other operating income, net   5   
Other undisclosed operating income (loss)   (1) 119
Operating loss:(41)(33)(40)(49)(117)(86)(42)
Nonoperating income (expense)14(1)(4)(4)(8)(2)
Investment income, nonoperating11     
Foreign currency transaction gain (loss), before tax(0)(0)1(0)(1)(4)0
Other nonoperating income (expense)14(0)(0)(1)(1) 
Interest and debt expense(1)(1)(0)(3)(1)(2)(1)
Loss before gain (loss) on sale of properties:(41)(31)(41)(56)(122)(96)(45)
Other undisclosed net income1103121
Net loss:(40)(29)(41)(53)(121)(94)(44)
Net income attributable to noncontrolling interest0001111
Net loss attributable to parent:(40)(29)(41)(52)(119)(93)(43)
Preferred stock dividends and other adjustments (0)(4) (3)(3)(7)
Net loss available to common stockholders, diluted:(40)(29)(45)(52)(123)(96)(50)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(40)(29)(41)(53)(121)(94)(44)
Other comprehensive income (loss)(1)(4)00(0)2(0)
Comprehensive loss:(41)(34)(40)(53)(121)(92)(44)
Comprehensive income (loss), net of tax, attributable to noncontrolling interest000111(1)
Other undisclosed comprehensive income, net of tax, attributable to parent      2
Comprehensive loss, net of tax, attributable to parent:(41)(34)(40)(52)(120)(91)(43)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: